Golden, Colorado-July13th, 2020-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro
Biopharma, announced that Jack Zamora has joined its executive team as its Chief Medical Advisor (“CMA”).

Dr. Jim Musick, CEO of Vitro Biopharma, said, “We are pleased to have Jack on our executive team and advisory board. Jack brings clinical medical, and research and development experience to Vitro that is synergistic with our stem cell science AlloRx Stem Cells™. Jack is already involved in our COVID-19 IND filings and our partnership with GIOSTAR. We have an exclusive worldwide distribution agreement with InfiniveMD.

Dr. Zamora graduated from Tulane University School of Medicine and completed his internship, residency, and a fellowship in oculoplastics at Boston University. He was an assistant professor at Boston University and was recognized as one of the premier surgical instructors.

Dr. Zamora has been practicing in Denver for the last 16 years and is known worldwide for the creation of the novel subdermal plasma energy technique in skin tightening and body and facial contouring using Bovie’s J-plasma device (renamed APYX, Renuvion). Dr. Zamora has served on the Medical Advisory Board of APYX, he has relationships with distributors and surgeons throughout the world from teaching his leading techniques to
plastic surgeons in the Middle East, Latin America, and the United States.

Dr. Zamora collaborated with Vitro in August of 2018 in the development and distribution of Vitro’s stem cell-based cosmetic line, private labeled for global distribution by lnfiniVive MDa medical device and stem cell skincare distribution company. lnfiniVive MD, led by Dr. Zamora, is committed to delivering the world’s most unique cosmetic stem cell-based skin care system and the most advanced energy medical devices and protocols to aesthetic practices worldwide.

Dr. Zamora said, “In a joint development effort with Vitro we have developed the world’s first topical cosmetic stem cell serum and topical cosmetic exosome serum. partners have been added and demand is growing, only set back by the pandemic, but is starting to resume and is positioned for global success.”

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward-looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues, and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Dr. James Musick
Chief Executive Officer
Vitro BioPharma
(303) 999-2130 Ext. 1
Source: Vitro Diagnostics, Inc.